Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
T-Rex 2X Long MSTR Daily Target ETFTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.71 (market cap $5.07B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.82. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.

ACADMSTU
Market Cap
$5.07B
Sector
HealthLeveraged / Inverse
52-Week High
$29.41$76.30
52-Week Low
$20.06$1.46
Enterprise Value
$4.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

T-Rex 2X Long MSTR Daily Target ETF

MSTU trades at $1.87, down 1.06% with a bearish technical outlook showing 15 sell signals versus 1 buy signal. The ETF has experienced significant value erosion, with recent articles highlighting a 98% loss from November 2024 levels despite a 10:1 reverse stock split. Technical indicators show moving averages are unanimously bearish while oscillators remain neutral, with support and resistance clustered around $2.

The outlook remains challenging given the ETF's leveraged structure and substantial historical losses. Investment opportunity exists only for sophisticated traders comfortable with high volatility, while risks include daily rebalancing effects and continued erosion of value in declining markets. The fund's performance remains tightly coupled to its underlying asset's volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About T-Rex 2X Long MSTR Daily Target ETF

MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.

Read more on MSTU